1 **Title**

2 **The structure of the neurotoxin palytoxin determined by MicroED**

3

4 **Authors**

5 **Cody Gillman[1,2], Khushboo Patel[1], Johan Unge[1], Tamir Gonen[1,2,3,4*]**

6 **Affiliations**

7 [1] Department of Biological Chemistry, University of California, Los Angeles CA, USA

8 [2] Molecular Biology Institute, University of California, Los Angeles CA, USA

9 [3] Department of Physiology, University of California, Los Angeles CA, USA

10 [4] Howard Hughes Medical Institute, University of California, Los Angeles CA, USA

11 * To whom correspondence should be sent T.G. tgonen@g.ucla.edu

12

13 **Keywords**

14 Microcrystal electron diffraction, MicroED, CryoEM, FIB milling, FIB/SEM, neurotoxin, ATPase

15

16 **Abstract**

17 Palytoxin (PTX) is a potent neurotoxin found in marine animals that can cause serious symptoms
18 such as muscle contractions, haemolysis of red blood cells and potassium leakage. Despite years
19 of research, very little is known about the mechanism of PTX. However, recent advances in the
20 field of cryoEM, specifically the use of microcrystal electron diffraction (MicroED), have allowed
21 us to determine the structure of PTX. It was discovered that PTX folds into a hairpin motif and is
22 able to bind to the extracellular gate of Na,K-ATPase, which is responsible for maintaining the
23 electrochemical gradient across the plasma membrane. These findings, along with molecular
24 docking simulations, have provided important insights into the mechanism of PTX and can
25 potentially aid in the development of molecular agents for treating cases of PTX exposure.

26

27 **Introduction**

28 Na,K-ATPase is an essential protein for maintaining proper cell function and is targeted by the
29 potent marine toxin palytoxin (PTX) (Habermann, 1989; Christian Skou & Esmann, 1992; Tubaro
30 *et al.*, 2012). PTX is a non-proteinaceous natural product that was first isolated from tropical
31 marine corals and later found in dinoflagellates(Usami *et al.*, 1995; Taniyama *et al.*, 2003; Ukena
32 *et al.*, 2014; Moore & Scheuer, 1971). PTX can accumulate to dangerous levels in seafood,
33 leading to serious illness and death in those who consume it (Patocka *et al.*, 2015; Deeds &
34 Schwartz, 2010; Fukui *et al.*, 1987; Rhodes *et al.*, 2002). Aquarium hobbyists may also be
35 exposed to PTX when mishandling Palythoa coral or inhaling aerosolized PTX (Hoffmann *et al.*,
36 2008; Rumore & Houst, 2014). Inhaling PTX from blooming events of *Ostreopsis* has also caused

37 severe illness and hospitalization (Ciminiello *et al.*, 2006). Understanding the structure of PTX
38 and how it binds to Na,K-ATPase is crucial for developing molecular agents that can treat cases
39 of PTX exposure and protect against its toxic effects.

40 PTX's binding to Na,K-ATPase with high affinity and its ability to convert it into a passive cation
41 pore has serious implications for cellular function and can lead to a range of health effects,
42 including skeletal muscle contractions, heart failure, hemolysis, and platelet aggregation
43 (Böttinger *et al.*, 1986; Riobó & Franco, 2011; Artigas & Gadsby, 2003; Wang & Horisberger,
44 1997). The irreversible depolarization of the membrane caused by PTX can also contribute to
45 bone resorption and tumorigenesis (Lazzaro *et al.*, 1987; Aligizaki *et al.*, 2011). The extremely
46 low lethal dose for humans highlights the severity of PTX poisoning (Tubaro *et al.*, 2011; Wiles *et*
47 *al.*, 1974).

48 The development of anti-PTX molecules that can inhibit the binding of PTX on Na,K-ATPase is
49 crucial for the treatment of PTX exposure. The structure of PTX when bound to an antibody
50 fragment (scFv) was determined using microcrystal electron diffraction (MicroED) (Shi *et al.*,
51 2013; Nannenga *et al.*, 2014)at 3.2 Å resolution. This provided valuable information on the binding
52 mode of PTX, which was then used to perform docking simulations to determine the potential
53 binding mode of PTX on Na,K-ATPase. These findings pave the way for the development of
54 molecular agents that can treat cases of PTX exposure by inhibiting the binding of PTX on Na,K-
55 ATPase, and can potentially save many lives.
56
57
58 **Results**

59 ***Characterization of scFv-PTX complex and crystallization***

60 To date, very little has been uncovered about the three-dimensional structure of PTX. Many
61 studies have utilized anti-PTX antibodies to investigate PTX (Lau *et al.*, 1995; Taniyama *et al.*,
62 2003; Levine *et al.*, 1987). The scFv antibody used in this study is a 26 kDa protein developed,
63 expressed, and purified by Zabbio (San Diego, CA). The binding of PTX to scFv was confirmed
64 using size exclusion chromatography (SEC). The shift in the SEC trace of free scFv and PTX-
65 bound scFv was compared to confirm binding (Figure 1A). Furthermore, the binding affinity of
66 PTX to scFv was determined using microscale thermophoresis (MST). PTX binds to scFv at a
67 K_D of 2.1 µM (Figure 1B).

68 SEC fractions corresponding to the stable scFv-PTX complex were collected, concentrated to 10
69 mg/mL, and subjected to sparse matrix crystallization screening to identify crystallization condition
70 hits. The scFv-PTX complex was crystallized by the hanging drop vapor diffusion technique. The
71 well solution contained 27 % Jeffamine ED-2001 pH 7.0 and 100 mM sodium citrate tribasic
72 dihydrate pH 5.6. The scFv-PTX complex was combined with the well solution at 2:1 (v/v) ratio.
73 The crystals were thin rods that formed in dense bundles (Figure 1C). The average size of each
74 crystal was 5 µm x 500 µm. The crystals in the drop were then transferred to an electron
75 microscopy (EM) sample grid, blotted to remove surrounding crystallization media, and vitrified
76 by plunge freezing into liquid ethane. Crystals were stored in liquid nitrogen prior to use.
77

78 ***Preparaing crystal lamellae and collection of MicroED data***

79 The crystals that were obtained for this study were too thick for MicroED and needed to be thinned
80 to a thickness that would allow for the transmission of electrons (Martynowycz *et al.*, 2021). To
81 achieve this, thin crystal lamellae were produced using a cryogenic focused ion beam scanning

82 electron microscope (FIB/SEM) milling instrument (Martynowycz *et al.,* 2019). The process began
83 by loading the EM grid with crystals into the FIB/SEM at cryogenic temperature, followed by
84 imaging using the SEM (Figure 1D). Potential milling sites were then observed in the FIB view of
85 the specimen (Figure 1E), and the targeted crystal and surrounding media were milled into a thin
86 lamella using the gallium ion beam. The final product was a lamella that measured 7 μm wide and
87 300 nm thick.

88 After the crystal lamellae were produced, they were transferred to a Titan Krios transmission
89 electron microscope that was operating at 300 kV and cooled cryogenically. The sites of the
90 lamellae were identified using low magnification imaging and adjusted to eucentric height. To
91 ensure high-resolution diffraction, a preview of the lamella was taken (Figure 1F and 2A). The
92 data was collected using continuous rotation MicroED (Nannenga *et al.*, 2014), with a Falcon4
93 direct electron detector set to counting mode. The highest resolution spots were observed at 3.2
94 A resolution.

95 ***Determining the MicroED structure of scFv-PTX complex.*** MicroED data were converted to
96 standard crystallographic formats using software freely available on our website
97 (https://cryoem.ucla.edu/microed). The data were indexed and integrated in XDS (Kabsch,
98 2010*b*) to a resolution of 3.2 Å, which corresponds to where the CC1/2 was approximately 32%.
99 Reflection data from three crystal lamellae were merged to increase completeness. Phases for
100 the MicroED reflections were determined by molecular replacement using scFv 4B08 (PDB 5YD3)
101 (Miyanabe *et al.*, 2018) as a search model. scFv 4B08 and scFv have 45% sequence identity.
102 The space group was determined to be $P4_12_12$ and unit cell dimensions were 69.95, 69.95, 289.48
103 (a, b, c) (Å) and 90, 90, 90 (α, β, γ) (°). The structure was refined using electron scattering factors
104 (Table 1) using phenix.refine (Afonine *et al.*, 2012). The scFv-PTX complex is in dimeric form with
105 one PTX bound to each scFv monomer. The density map contoured at 1.5 σ had continuous
106 density for the backbone of the scFv and the side chains of the amino acids were also well
107 resolved (Figure 2B). Continuous density was obtained for PTX after multiple rounds of refinement
108 (Figure 2C). The R_{work} and R_{free} of the refinement were 28% and 32%, respectively.

109 ***The MicroED structure of scFv-PTX complex.***
110 The scFv creates a binding pocket into which an internal segment of the PTX chain is inserted,
111 forming a hairpin motif (depicted in Figure 3). The deepest part of the pocket consists of a double
112 ring with two cyclic ethers, which is flanked by two hydrocarbon chains running antiparallel to
113 each other. Hydrogen bonds are formed between a cyclic ether of the double ring and residues
114 Y106, E108, and Y169 of the scFv. Hydrophobic amino acid side chains, including F59, W224,
115 V231, and V165, sequester the hydrophobic segments of PTX flanking the double ring from the
116 external aqueous environment. At the entrance to the binding pocket, a network of intramolecular
117 hydrogen bonds is formed by several hydroxyl groups. Outside the binding pocket, the two tail
118 ends of PTX are observed traveling in opposite directions in the solvent channel of the crystal.
119
120 ***Molecular docking.***
121 The scFv-PTX complex structure obtained by MicroED was used to investigate the potential
122 binding of PTX to the Na,K-ATPase protein using molecular docking. The hairpin-like motif of PTX
123 from the scFv-PTX complex was used as the ligand, and the human Na,K-ATPase structure in
124 E1 state was used as the receptor protein molecule (Guo *et al.*, 2022). Rigid docking simulations
125 were performed using the Patchdock server (Schneidman-Duhovny *et al.*, 2005), which
126 suggested that the hairpin motif of PTX binds to the extracellular gate of the Na,K-ATPase protein.
127 The cyclic ether forms hydrogen bonds, while the hydrocarbon chains are protected by
128 hydrophobic transmembrane alpha-helices. The two tails of PTX are between the alpha and beta

3

129 subunits of Na,K-ATPase. Flexible docking simulations were performed using Autodock Vina
130 (Trott & Olson, 2009) to further confirm the Patchdock results. The results indicated that the
131 hairpin motif of PTX could bind to the similar binding pocket in the Na,K-ATPase, forming a plug-
132 like structure that blocks the channel, thereby rendering it inactive. This is consistent with
133 previously reported functional assays (Vale & Ares, 2007; Ramos & Vasconcelos, 2010). Both
134 binding simulations suggest that PTX's hairpin motif could potentially bind to the Na,K-ATPase
135 and block the channel, leading to a possible explanation for the cytotoxic effects of PTX.
136

Discussion

138 The findings of this study provide significant insights into the molecular mechanism of PTX binding
139 to Na,K-ATPase. The hairpin motif formed by the hydrophobic region of PTX when bound to scFv
140 was found to also fit into the extracellular gate of Na,K-ATPase like a plug, blocking the ion
141 channel and rendering the pump inactive. This corroborates earlier reports that this region of PTX
142 is chiefly responsible for its interaction with biomembranes and may be important in the
143 conversion of Na,K-ATPase from a pump to a passive cation pore (Harmel & Apell, 2006;
144 Habermann *et al.*, 1981). The molecular docking simulations performed in this study provide a
145 model of how PTX binding to Na,K-ATPase takes place and the results suggest that PTX likely
146 adopts the same hairpin fold when bound to Na,K-ATPase. Overall, this study represents an
147 important step towards a better understanding of the molecular mechanisms involved in PTX
148 binding and its effects on Na,K-ATPase.

149 The use of scFv in this study allowed for the determination of the 3D structure of the scFv-PTX
150 complex using MicroED. The scFv-PTX complex was crystallized using the hanging drop vapor
151 diffusion method, and the crystals were thinned using cryogenic FIB milling prior to MicroED
152 diffraction. The needle-shaped crystals of the scFv-PTX complex that were obtained for this study
153 were typically thin (3-5 μm) and long (several hundred microns) and they formed in bundles. Such
154 morphologies are extremely challenging for analyses by x-ray crystallography, often leading to
155 multiple lattices and weak scattering. Using MicroED and FIB milling was advantageous in this
156 case because the entire crystal bundle could be transferred to the EM grid and crystal sites were
157 accessed by using a FIB mill to generate crystal lamellae and ultimately a MicroED structure.

158 The structure showed that PTX binds to the scFv in a highly specific manner, forming several key
159 interactions with amino acid residues in the complementarity-determining regions (CDRs) of the
160 scFv. In particular, PTX binds to the CDR H3 loop of the scFv, which is known to be a critical
161 region for antigen binding (Figure 2B). The 3D binding mode of PTX to scFv was used to perform
162 docking simulations to predict the binding mode of PTX to Na,K-ATPase. The docking simulations
163 suggested that PTX binds to Na,K-ATPase in a similar manner to scFv, with the key interactions
164 occurring in the extracellular ion gate of Na,K-ATPase (Figure 3). This provides important insights
165 into the mechanism of PTX binding to Na,K-ATPase and can aid in the development of anti-PTX
166 molecules that prevent the binding of PTX to Na,K-ATPase.

167 This research paves the way for the development of possible treatments for PTX exposure. The
168 detailed structural information obtained from our MicroED study can aid in the creation of new
169 inhibitors that can block the binding of PTX to Na,K-ATPase, thus preventing its toxic effects.
170 Additionally, the knowledge gained from this study can be applied to develop methods for
171 identifying and monitoring the accumulation of PTX and its analogues in the environment,
172 potentially preventing harmful exposure to both humans and marine life. In summary, this
173 research not only elucidates the mechanism of action of PTX, but also offers valuable insights

174 into the development of potential therapeutics and environmental monitoring techniques.
175 Significantly, this study reinforces the utility of MicroED as a powerful tool for revealing the
176 structures of important biomolecules, such as the long-awaited structure of palytoxin, which has
177 been elusive to x-ray crystallography.

178

Acknowledgments

185

Figure Legends

187 **Figure 1. Crystallization of scFv-PTX** (a) Overlay of size-exclusion chromatography traces of
188 scFv alone (blue trace) and scFv-PTX complex (orange trace). (b) Microscale thermophoresis
189 binding assay confirming binding between scFv-PTX complex. This assay indicates that palytoxin
190 binds to ScFv with K_D = 2.1 μM affinity (c) Light microscope image of scFv-PTX complex crystals
191 (d) SEM image of crystals viewed normal to the grid support surface prior to FIB milling. Scale
192 bar = 200 μm. (e) FIB image of a crystal milling site. Scale bar = 10 μm. (f) Lamella imaged normal
193 to the grid surface in the TEM after milling. Scale bar = 10 μm. The lamella was 200nm thick.

194 **Table 1. MicroED structure statistics of scFv-PTX complex.**

195 **Figure 2. The MicroED structure of PTX in complex with scFv.** (a) Representative MicroED
196 image. The highest resolution spots were observed at 3.2 Å (red arrowhead). (b) Structure of
197 scFv-PTX complex. The scFv is represented as a cartoon in grey and PTX is represented as a
198 surface model in blue. A beta-strand was selected (red) to provide a sample of the 2mFo–DFc
199 map (blue mesh), which was contoured at 1.5 σ with a 2-Å carve. (c) The overall 2mFo–DFc map
200 of density for both PTX (solid blue) and scFv (solid white) in complex. The density map was
201 contoured at 1.5 σ.

202 **Figure 3. Binding interactions between scFv and PTX.** An internal region of PTX (represented
203 as yellow carbons and heteroatoms) folds into a hairpin motif and inserts into the scFv binding
204 pocket. A double ring of PTX forms several H-bonding interactions with polar amino acid side
205 chains at the deepest part of the scFv binding pocket (Y101, Y106, E108). A belt of hydrophobic
206 amino acid side chains interact with the hydrophobic chains of PTX (V165, V231, W224, F59).
207 Additional H-bond interactions take place near the mouth of the binding pocket (N164, W33,
208 Y101).

209 **Figure 4: Molecular docking of PTX to Na,K – ATPase.** (A) Comparison of binding modes of
210 PTX to scFv and Na,K – ATPase. The hairpin motif of PTX shown as yellow sticks interacts with
211 both scFv shown as white surface and Na, K – ATPase shown as cyan and salmon pink ribbons.
212 (B) Surface representation of Na,K-ATPase shows that the hairpin motif of PTX binds the
213 extracellular gate of the pump in a plug-like manner.

Figure 5: Comparison of top docking solutions from patchdock and autodock vina. The patchdock solution (yellow sticks) and vina solution (grey sticks) show that the finger motif of PTX binds to the extracellular gate of the Na,K-ATPase. In both solutions, the double ring (highlighted by red circle) interacts with Na,K-ATPase by forming hydrogen bonds and the surrounding helices form hydrophobic interactions with the hydrocarbon chains of the hairpin motif.

Methods and Materials

Materials. All reagents were made with MilliQ water. Palytoxin was purchased from Fuji Film (Japan). Crystallization reagents were purchased from Hampton Research (Aliso Viejo, CA). Monolith protein labeling kit RED-NHS 2nd generation was purchased from NanoTemper Technologies (Munich, Germany).

Microscale thermophoresis. The anti-PTX scFv was prepared in 25 mM HEPES (pH 7.4), 150 mM NaCl at a concentration of 13 µM, and labeled with RED-NHS dye (NanoTemper) . PTX was prepared in 25 mM HEPES (pH 7.4), 150 mM NaCl at a concentration of 93 µM. Labeled scFv was diluted to 80 nM and added in a 1:1 ratio to a dilution series of 46.5 µM down to 4.65×10^{-15} µM of PTX and 0 µM of PTX. Mixtures were loaded into premium capillaries (Monolith Capillaries, NanoTemper Technologies). Thermophoresis was measured at 21°C for 15 sec with 50% LED power and 100% (auto-detect) power.

Crystallization. The complex was purified by size-exclusion chromatography and the elution fractions were concentrated to 10 mg/mL. Palytoxin was incubated with scFv at a 2:1 molar ratio for 30 minutes at room temperature. A sparse matrix screening hit was identified in the PEGRxHT well condition C01 (Hampton Research) by sitting drop vapor diffusion using a Mosquito crystallization robot. This condition was optimized for robust crystallization using hanging drop vapor diffusion. In the final condition, the complex was crystallized by mixing with 27 % Jeffamine ED-2001 pH 7.0, and 100 mM sodium citrate tribasic dihydrate pH 5.6 in 1.5 uL drops with a 2:1 sample-to-mother liquor ratio.

Cryo-preservation. The cover slip with crystal drop was removed from the screening tray and the drop was gently applied to a Cu200 R2/2 holey carbon EM grid (quantifoil). The EM grid was negatively glow-discharged prior to sample application. The grid was blotted in a Leica GP2 set to 95% humidity and 12°C and plunge-frozen into liquid ethane. The sample was stored in liquid nitrogen until further use.

Machining crystal lamellae using the cryo-FIB/SEM. The vitrified EM grid was loaded into a Thermo Fisher Aquilos dual-beam FIB/SEM operating at cryogenic temperature following established procedures (Martynowycz *et al.*, 2019). The sample was sputter coated with a thin layer of platinum to preserve the sample during imaging and ion beam milling. A whole-grid atlas of the drop was acquired by the SEM and potential milling sites were selected. The targeted crystal and surrounding media were milled into a thin lamella using the gallium ion beam. The first stage of milling used a beam current of 0.5 nA and gradually decreased to a minimum of 10 pA as the lamella became thinner at later stages of milling. The final lamellae were 7 µm wide and 200 nm thick.

MicroED Data Collection. Grids with milled lamellae were transferred to a cryogenically cooled Thermo Fisher Scientific Titan Krios G3i TEM operating at an accelerating voltage of 300 kV. The

256 Krios was equipped with a field emission gun and a Falcon4 direct electron detector. A low
257 magnification atlas of the grid was acquired using EPUD (Thermo Fisher) to locate milled
258 lamellae. The stage was translated to the lamellae position and the eucentric height was set. The
259 100 μm selected area aperture was inserted and centered on the crystal to block background
260 reflections. In diffraction mode, the beam was defined using a 50 μm C2 aperture, a spotsize of
261 11, and a beam diameter of 20 μm. MicroED data were collected by continuously rotating the
262 stage at 0.2 ° / s. MicroED data from three different crystal lamellae were selected for downstream
263 data processing.

264 ***MicroED Data Processing.*** Diffraction movies in MRC format were converted to SMV format
265 using MicroED tools (https://cryoem.ucla.edu/microed) (Martynowycz *et al.*, 2019; Hattne *et al.*,
266 2015). The diffraction dataset was indexed and integrated in *XDS* (Kabsh, 2010). Integrated
267 intensities from three different crystal lamella were merged and scaled in *XSCALE* (Kabsch,
268 2010*a*).

269 ***Structure solution and refinement.*** Phases for the MicroED reflections were determined by
270 molecular replacement in PHASER (McCoy *et al.*, 2007) using anti-Mcl1 scFv (PDB 6QF9) as the
271 search model (Luptak *et al.*, 2019). The solution was space group $P4_12_12$ and unit cell dimensions
272 69.95, 69.95, 289.48 (a, b, c) (Å) and 90, 90, 90 (α, β, γ) (°). The first refinement was performed
273 with Coot and phenix.refine (Afonine *et al.*, 2012) using isotropic B-factors and electron scattering
274 factors. Occupancies were refined for alternative side chain conformations and SO_4 and waters
275 were manually placed during refinement. The final refinement used anisotropic B-factors,
276 automatic water picking, and electron scattering factors and resulted in R_{work}/R_{free} = 0.2830/0.3229
277 and resolution of 3.2 Å.

278 ***Molecular docking.*** A human Na,K-ATPase structure in E1 state (PDB ID: 7E21) (Guo *et al.*,
279 2022) without cofactors, waters and ligands was used as a receptor molecule and the 3D model
280 of PTX from the scFv-PTX complex was used as a rigid ligand. For patchdock simulations, the
281 PDB files of receptor and ligand molecules were submitted to the patchdock server
282 (http://bioinfo3d.cs.tau.ac.il/PatchDock/php.php). The clustering RMSD was selected to be 4.0
283 and the complex type was selected to be protein-ligand complex. The results were emailed within
284 24h with a list of potential binding solutions of PTX numbered on the basis of geometric shape
285 complementarity score. Higher complementarity scores indicate less possibility of steric clashes
286 in the solution.

287 Full length PTX did not provide any solution when simulation was performed using Autodock vina,
288 hence, a flexible fragment of PTX molecule consisting of only the hairpin motif was used to
289 perform the binding simulations. The receptor and ligand were prepared using the MGL tools suite
290 (https://ccsb.scripps.edu/mgltools/) and saved as pdbqt files. The receptor file contained partial
291 charges and polar hydrogens. Any cofactors, waters and ligands were removed. For the ligand
292 file, polar hydrogens were added and all the original torsion angles were kept intact. The receptor
293 was treated as rigid but the ligand fragment was flexible. The simulations were run and the
294 solutions were scored on the basis of binding energy (kcal/mol).

295
296

297

298

299

References

300

301 Afonine, P. V., Grosse-Kunstleve, R. W., Echols, N., Headd, J. J., Moriarty, N. W.,
302   Mustyakimov, M., Terwilliger, T. C., Urzhumtsev, A., Zwart, P. H. & Adams, P. D. (2012).
303   *Acta Crystallogr D Biol Crystallogr* **68**, 352–367.

304 Aligizaki, K., Katikou, P., Milandri, A. & Diogène, J. (2011). *Toxicon* **57**, 390–399.

305 Artigas, P. & Gadsby, D. C. (2003). *Proc Natl Acad Sci U S A* **100**, 501–505.

306 Böttinger, H., Béress, L. & Habermann, E. (1986). *BBA - Biomembranes* **861**, 165–176.

307 Christian Skou, J. I. & Esmann, M. I. (1992). *J Bioenerg Biomembr* **24**.

308 Ciminiello, P., Dell'Aversano, C., Fattorusso, E., Forino, M., Magno, G. S., Tartaglione, L., Grillo,
309   C. & Melchiorre, N. (2006). *Anal Chem* **78**, 6153–6159.

310 Deeds, J. R. & Schwartz, M. D. (2010). *Toxicon* **56**, 150–162.

311 Fukui, M., Murata, M., Inoue, A., Gawel, M. & Yasumoto, T. (1987). *Toxicon* **25**, 1121–1124.

312 Guo, Y., Zhang, Y., Yan, R., Huang, B., Ye, F., Wu, L., Chi, X., shi, Y. & Zhou, Q. (2022). *Nat*
313   *Commun* **13**, https://doi.org/10.1038/s41467-022-31602-y.

314 Habermann, E. (1989). *Toxicon* **27**, 1171–1187.

315 Habermann, E., Ahnert-Hilger, G., Chhatwal, G. S. & Beress, L. (1981). *Biochimica et*
316   *Biophysica Acta (BBA) - Biomembranes* **649**, 481–486.

317 Harmel, N. & Apell, H.-J. (2006). *J Gen Physiol* **128**, 103–118.

318 Hattne, J., Reyes, F. E., Nannenga, B. L., Shi, D., De La Cruz, M. J., Leslie, A. G. W. & Gonen,
319   T. (2015). *Acta Crystallogr A Found Adv* **71**, 353–360.

320 Hoffmann, K., Hermanns-Clausen, M., Buhl, C., Büchler, M. W., Schemmer, P., Mebs, D. &
321   Kauferstein, S. (2008). *Toxicon* **51**, 1535–1537.

322 Kabsch, W. (2010*a*). *Acta Crystallogr D Biol Crystallogr* **66**, 133–144.

323 Kabsch, W. (2010*b*). *Acta Crystallogr D Biol Crystallogr* **66**, 125–132.

324 Kabsh, W. (2010). *Acta Crystallogr D Biol Crystallogr* **66**, 125–132.

325 Lau, C. O., Tan, C. H., Khoo, H. E., Yuen, R., Lewis, R. J., Corpuz, G. P. & Bignami, G. S.
326   (1995). *Toxicon* **33**, 1373–1377.

327 Lazzaro, M., Tashjian Jr., A., Fujiki, H. & Levinef, L. (1987). *Endocrinology* **120**, 1338–1345.

328 Levine, L., Fujiki, H., Gjika, H. B. & Van Vunakis, H. (1987). *Toxicon* **25**, 1273–1282.

329 Luptak, J., Bista, M., Fisher, D., Flavell, L., Gao, N., Wickson, K., Kazmirski, S. L., Howard, T.,
330   Rawlins, P. B. & Hargreaves, D. (2019). *Acta Crystallographica Section D* **75**, 1003–1014.

331 Martynowycz, M. W., Clabbers, M. T. B., Unge, J., Hattne, J. & Gonen, T. (2021). *Proc Natl*
332   *Acad Sci U S A* **118**, 1–7.

333 Martynowycz, M. W., Zhao, W., Hattne, J., Jensen, G. J. & Gonen, T. (2019). *Structure* **27**, 545-
334   548.e2.

335 McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C. & Read, R. J.
336   (2007). *J Appl Crystallogr* **40**, 658–674.

337 Miyanabe, K., Akiba, H., Kuroda, D., Nakakido, M., Kusano-Arai, O., Iwanari, H., Hamakubo, T.,
338   Caaveiro, J. M. M. & Tsumoto, K. (2018). *The Journal of Biochemistry* **164**, 65–76.

339 Moore, R. E. & Scheuer, P. J. (1971). *Science (1979)* **172**, 495–498.

340 Nannenga, B. L., Shi, D., Leslie, A. G. W. & Gonen, T. (2014). *Nat Methods* **11**, 927–930.

341 Patocka, J., Gupta, R. C., Wu, Q. & Kuca, K. (2015). *Journal of Huazhong University of Science*
342   *and Technology [Medical Sciences]* **35**, 773–780.

343 Ramos, V. & Vasconcelos, V. (2010). *Mar Drugs* **8**, 2021–2037.

344 Rhodes, L., Towers, N., Briggs, L., Munday, R. & Adamson, J. (2002). *N Z J Mar Freshwater*
345   *Res* **36**, 631–636.

346 Riobó, P. & Franco, J. M. (2011). *Toxicon* **57**, 368–375.

347 Rumore, M. M. & Houst, B. M. (2014). *Int J Case Rep Images* **5**, 501–504.

348 Schneidman-Duhovny, D., Inbar, Y., Nussinov, R. & Wolfson, H. J. (2005). *Nucleic Acids Res*
349   **33**, W363–W367.

350 Shi, D., Nannenga, B. L., Iadanza, M. G. & Gonen, T. (2013). *Elife* **2**, e01345.

351 Taniyama, S., Arakawa, O., Terada, M., Nishio, S., Takatani, T., Mahmud, Y. & Noguchi, T.
352   (2003). *Toxicon* **42**, 29–33.

353 Trott, O. & Olson, A. J. (2009). *J Comput Chem* NA-NA.

354 Tubaro, A., Durando, P., Del Favero, G., Ansaldi, F., Icardi, G., Deeds, J. R. & Sosa, S. (2011).
355   *Toxicon* **57**, 478–495.

356 Tubaro, A., Sosa, S. & Hungerford, J. (2012). Toxicology and diversity of marine toxins.
357   Veterinary toxicology: basic and clinical principles Academic press.

358 Ukena, T., Satake, M., Usami, M., Oshima, Y., Naoki, H., Fujita, T., Kan, Y. & Yasumoto, T.
359   (2014). *Biosci Biotechnol Biochem* **65**, 2585–2588.

360 Usami, M., Satake, M., Ishida, S., Inoue, A., Kan, Y. & Yasumoto, T. (1995). *J Am Chem Soc*
361   **117**, 5389–5390.

362 Vale, C. & Ares, I. R. (2007). *Phycotoxins: Chemistry and Biochemistry* 95–118.

363 Wang, X. & Horisberger, J. D. (1997). *FEBS Lett* **409**, 391–395.

364 Wiles, J. S., Vick, J. A. & Christensen, M. K. (1974). *Toxicon* **12**, 427–433.

365

366

Figure 1

384

Table 1

Data	Parameter	Measure
Data Collection	Accelerating voltage (kV)	300
	Electron source	field emission gun
	Total accumulated exposure (e⁻/Å²)	0.64
	Microscope	Thermo Fisher Titan Krios
	Camera	Falcon 4 electron counting
	Rotation rate (deg/sec)	0.2
	Wavelength (Å)	0.019687
Data analysis	No. of crystals	3
	Resolution range (Å)	46.80-3.20
	Space group	$P4_12_12$
	a, c, c (Å)	69.95, 69.95, 289.48
	α, β, ϒ (°)	90, 90, 90
	Reflections, total/unique	260311/12734
	Multiplicity	20.44
	Completeness (%)	99.3
	Mean I/Iσ(I)	2.59
	CC1/2	95.3
	Rwork	0.2830
	Rfree	0.3229

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

Figure 2

Figure 3

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

13

Figure 4

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

14

456

457

458   **Figure 5**

459